Concepedia

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis, Sebastian Grosicki, Michèle Cavo, Meral Beksaç, Wojciech Legieć, Anna Marina Liberati, Hartmut Goldschmidt, Andrew R. Belch,

The Lancet Haematology · 2022 · 47 citations · 27 references

DOI

Concepts

References

27

International uniform response criteria for multiple myeloma

Brian G.M. Durie, J-L Harousseau, Jesús F. San Miguel et al. · Leukemia · 2006 · 2.6K citations

, , +12

CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

Joan Bladé, Diana Samson, Donna Reece et al. · British Journal of Haematology · 1998 · 1.5K citations

, , +17

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

Shaji Kumar, Angela Dispenzieri, Martha Q. Lacy et al. · Leukemia · 2013 · 1.4K citations · Full text

, , +12

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Sagar Lonial, Meletios Α. Dimopoulos, Antonio Palumbo et al. · New England Journal of Medicine · 2015 · 1.3K citations · Full text

, , +16

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Philippe Moreau, Tamás Masszi, Norbert Grząśko et al. · New England Journal of Medicine · 2016 · 1.1K citations · Full text

, , +14